USPTO Examiner MOU LIYUAN - Art Unit 1628

Examiner Information

Name: MOU, LIYUAN
Art Unit: 1628
Total Cases: 96
Last Active: January 2025

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19038532WRN INHIBITORSJanuary 2025March 2025Allow200YesNo
18632351FIVE-MEMBERED-FUSED SIX-MEMBERED COMPOUND, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USEApril 2024February 2025Allow1121YesNo
18621023PHARMACEUTICAL COMPOSITIONS COMPRISING (2S)-N-{(1S)-1-CYANO-2-[4-(3-METHYL-2-OXO-2,3-DIHYDRO-1,3-BENZOXAZOL-5-yl)PHENYL]ETHYL}-1,4- OXAZEPANE-2-CARBOXAMIDEMarch 2024September 2024Allow510YesNo
18537729PYRROLO[3,2-C]ISOQUINOLINE-2,3-DIONE COMPOUNDS AS CK2 INHIBITORSDecember 2023February 2025Allow1420YesNo
18529147Methods For Treating Agitation In Subjects With Mild Cognitive Impairment Or Major Neurocognition DisorderDecember 2023June 2025Abandon1820YesNo
185113187H-PYRIDO[4',3':4,5]PYRROLO[2,3-C][1,7]NAPHTHYRIDINE COMPOUNDS AS CK2 INHIBITORSNovember 2023February 2025Allow1520YesNo
18388070RAPIDLY ACCELERATED FIBROSARCOMA (RAF) DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USENovember 2023June 2024Allow700YesNo
18470697COMPOSITIONS AND METHODS FOR DELIVERY OF PSILOCIN AND PRODRUGS THEREOFSeptember 2023May 2025Abandon2001NoNo
18370005TREATMENT REGIMENS FOR EARLY IDIOPATHIC PARKINSON'S DISEASESeptember 2023October 2024Abandon1220NoNo
18243177RAPIDLY ACCELERATED FIBROSARCOMA (RAF) DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USESeptember 2023October 2023Allow100NoNo
18364827TREATMENTS FOR OBSESSIVE COMPULSIVE DISORDERAugust 2023September 2024Abandon1320YesNo
18347335SOLID FORM OF COMPOUNDJuly 2023March 2024Allow910YesNo
18213055COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTORJune 2023April 2024Allow1010NoNo
17991861READY TO USE, NORADRENALINE DRIP BAGS, HAVING LOW SUBVISIBLE PARTICLE COUNTSNovember 2022October 2024Abandon2321YesNo
17823275NASAL SPRAYAugust 2022December 2024Abandon2721NoNo
17835330TRICYCLIC HETEROCYCLES AS FGFR INHIBITORSJune 2022May 2025Allow3621YesNo
17720501COMPOSITIONS AND METHODS FOR DELIVERY OF PSILOCIN AND PRODRUGS THEREOFApril 2022November 2023Abandon1910NoNo
17719131PYRAZOLYL BICYCLIC AMINES AS CDK2 INHIBITORSApril 2022August 2024Abandon2811NoNo
17718673METHODS, DEVICES, AND SYSTEMS FOR TREATING LENS PROTEIN AGGREGATION DISEASESApril 2022March 2024Abandon2311NoNo
17716051COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ESTROGEN RECEPTORSApril 2022October 2024Abandon3021NoNo
17658587CBL-B MODULATORS AND USES THEREOFApril 2022February 2025Allow3431YesNo
17713691METHODS, DEVICES, AND SYSTEMS FOR TREATING LENS PROTEIN AGGREGATION DISEASESApril 2022January 2024Abandon2211NoNo
17693609NON-ORAL MEDICATED CANNABINOID COMPOSITIONS, METHODS OF MANUFACTURING, AND METHODS OF TREATMENTMarch 2022September 2023Abandon1801NoNo
17693197Modulators of STING (Stimulator of Interferon Genes)March 2022December 2023Allow2111NoNo
17685174RAC INHIBITION AS A NOVEL THERAPEUTIC STRATEGY FOR EGFR/HER2 TARGETED THERAPY RESISTANT BREAST CANCERMarch 2022February 2024Abandon2420NoNo
17680569BET INHIBITORS AS A TREATMENT FOR MYELOFIBROSISFebruary 2022March 2025Allow3631YesNo
17586939QUINOLINES AND AZAQUINOLINES AS INHIBITORS OF CD38January 2022December 2023Allow2211NoNo
17586477Use of Serotonin 5-HT1A Receptor Agonists to Treat Diseases Associated with Sudden Unexpected Death in EpilepsyJanuary 2022February 2024Allow2421YesNo
17584714INJECTABLE SOLUTION OF NOREPINEPHRINEJanuary 2022December 2023Abandon2311NoNo
17579876COMBINATION CANCER THERAPY WITH DYRK1 INHIBITORS AND INHIBITORS OF THE RAS-RAF-MEK-ERK (MAPK) PATHWAYJanuary 2022February 2024Abandon2511NoNo
17579053ORAL PHARMACEUTICAL COMPOSITION AND METHOD FOR DELIVERING NITRIC OXIDE TO A PATIENT'S CIRCULATORY SYSTEM OR BRAINJanuary 2022April 2024Abandon2721NoNo
17570463Stable Solutions of Immunomodulatory Imide Compounds for Parenteral UseJanuary 2022April 2025Allow3941YesNo
17645071COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH cGASDecember 2021April 2025Allow4021YesNo
17553340METHODS OF THROMBOPROPHYLAXISDecember 2021March 2024Abandon2720NoNo
17552622COMPOSITIONS AND METHODS FOR THE TREATMENT OF EYE CONDITIONSDecember 2021September 2023Abandon2110NoNo
17611824USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPTIC SPASMSNovember 2021May 2025Abandon4201NoNo
17527688COMPOSITIONS AND METHODS FOR DEEP DERMAL DRUG DELIVERYNovember 2021December 2023Abandon2511NoNo
17516420CRYSTALLINE FORMS OF A DEOXYCYTIDINE KINASE INHIBITOR AND USES THEREOFNovember 2021January 2024Abandon2721YesNo
17502761COMPOSITION FOR INCREASING PREGNANCY RATE OF RUMINANTS AND PREPARATION METHOD AND APPLICATION THEREOFOctober 2021July 2024Abandon3321NoNo
17441340SEROTONIN 5-HT2B INHIBITORY COMPOUNDSSeptember 2021January 2025Allow4011YesNo
17478462REPURPOSED ANTIBIOTICS FOR NON-NUCLEAR GENOTOXIC CHEMOTHERAPY AND PHARMACEUTICAL COMPOSITION FOR ANTI-CANCER CONTAINING THE SAMESeptember 2021February 2025Abandon4101NoNo
17472847CRYSTALLINE AND AMORPHOUS FORMS OF A COMPOUND FOR THE TARGETED DEGRADATION OF ESTROGEN RECEPTORSeptember 2021March 2024Allow3011YesNo
17437111MACROCYCLES WITH ANTIOXIDANT AND NEUROPROTECTIVE ACTIVITIESSeptember 2021December 2024Abandon3901NoNo
17404523Inhibitors of SARM1August 2021February 2025Allow4210YesNo
174304733-(1-OXO-5-(PIPERIDIN-4-YL)ISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOFAugust 2021May 2025Abandon4511NoNo
17430116NOVEL TRITERPENONE DERIVATIVES AS HIV INHIBITORSAugust 2021April 2025Allow4411YesNo
17398345SYNTHESIS OF QUINAZOLINE COMPOUNDSAugust 2021August 2024Allow3621YesNo
17427958CRYSTALLINE SOLID FORMS OF BARICITINIBAugust 2021April 2025Abandon4511NoNo
17391479METHODS AND COMPOSITIONS FOR MODULATING SPLICINGAugust 2021January 2025Abandon4101NoNo
17427496CRYSTAL OF DIARYLTHIOHYDANTOIN COMPOUNDJuly 2021March 2025Allow4311YesNo
17425701N-HETEROCYCLIC FIVE-MEMBERED RING-CONTAINING CAPSID PROTEIN ASSEMBLY INHIBITOR, PHARMACEUTICAL COMPOSITION AND USES THEREOFJuly 2021November 2024Allow4010YesNo
17375949COMBINATION DRUG FORMULATIONS INCLUDING ROTIGOTINE AND AN ACETYLCHOLINESTERASE INHIBITOR FOR THE TREATMENT OF NEURODEGENERATIVE DISEASESJuly 2021September 2023Abandon2611NoNo
17372158COMPOSITIONS FOR TREATMENT OF VIRAL INFECTIONSJuly 2021August 2023Abandon2510NoNo
17369235PROCESS FOR PRODUCTION OF A NANO-MICROEMULSION SYSTEM OF FERULICJuly 2021September 2023Abandon2610NoNo
17415712HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONSJune 2021December 2024Abandon4201NoNo
17295405N-ACYLATED FATTY AMINO ACIDS TO REDUCE ABSORPTION VARIABILITY IN CANNABINOID BASED COMPOSITIONSMay 2021January 2025Allow4411YesNo
17293358ANTIBACTERIAL COMPOUNDSMay 2021November 2024Abandon4201NoNo
17293446SUBSTITUTED 1,2,4-OXADIAZOLE, ITS APPLICATION AND A PHARMACEUTICAL PREPARATION COMPRISING ITMay 2021November 2024Abandon4201NoNo
17291681TREATING NON-ALCOHOLIC STEATOHEPATITIS WITH CCK INHIBITORSMay 2021November 2024Allow4210YesNo
17287467FUNCTIONALIZED AMINOTRIAZINESApril 2021April 2025Allow4811YesNo
17286103TOPOISOMERASE II CATALYTIC INHIBITOR COMPOUND THERAPEUTICS FOR CANCER TREATMENT, METHODS AND USESApril 2021September 2024Abandon4101NoNo
17227841NOVEL APPLICATION OF GZD824 AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF IN TREATING DISEASESApril 2021March 2025Abandon4720NoNo
17278416HETEROCYCLYL COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASEMarch 2021September 2024Abandon4201NoNo
17278527TREATMENT OF HEMATOLOGICAL MALIGNANCIES WITH INHIBITORS OF MENINMarch 2021July 2024Abandon4011NoNo
17277201ISOLATION AND CHARACTERIZATION OF ANTICANCER COMPOUND FROM SESUVIUM PORTULACASTRUM (L.) L.March 2021August 2024Abandon4110NoNo
17198479DELTA OPIOID AGONIST, MU OPIOID ANTAGONIST COMPOSITIONS AND METHODS FOR TREATING PARKINSONS DISEASEMarch 2021March 2025Abandon4820NoNo
17272299HETEROCYCLIC COMPOUNDS AS AHR MODULATORSFebruary 2021July 2024Abandon4101NoNo
17267510COMBINATION OF HISTONE DEACETYLASE INHIBITOR AND PROTEIN KINASE INHIBITOR AND PHARMACEUTICAL USE THEREOFFebruary 2021January 2024Abandon3520NoNo
17171528PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA SELECTIVE AGONISTS FOR INHIBITION OF RETINAL PIGMENT EPITHELIUM DEGENERATION OR GEOGRAPHIC ATROPHYFebruary 2021November 2024Abandon4511NoNo
17266141CRYSTAL POLYMORPH OF 8-BROMO-2-(1-METHYLPIPERIDIN-4-YLAMINO)-4-(4-PHENOXYPHENYLAMINO)PYRIDO[4,3-D]PYRIMIDIN-5(6H)-ONE HYDROCHLORIDE AND METHOD FOR PREPARING SAMEFebruary 2021April 2023Allow2610YesNo
17261954INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USEJanuary 2021March 2024Allow3811YesNo
17261407A SUBSTITUTED AMINO-PYRIMIDINE COMPOUND FOR USE IN A METHOD FOR TREATMENT AND PREVENTION OF MULTIPLE SCLEROSISJanuary 2021November 2024Allow4620NoNo
17260831PYRIDAZINONE DERIVATIVEJanuary 2021November 2024Abandon4621NoNo
17260892IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVES AS TRK INHIBITORSJanuary 2021February 2024Abandon3711NoNo
17258393COMPOUNDS FOR TREATMENT OF INFLAMMATORY BOWEL DISEASE AND METHODS THEREOFJanuary 2021June 2023Abandon2901NoNo
17258086CRYSTALLINE SALTS OF 5-METHYL-(6S)-TETRAHYDROFOLIC ACID AND L-LEUCINE ETHYL ESTERJanuary 2021November 2023Allow3410YesNo
16979610TUMOR IMMUNOMODULATORJanuary 2021January 2024Abandon4111NoNo
17257531COMPOSITIONS AND METHODS TARGETING GLUTAMINE AND ITS METABOLISM FOR DIAGNOSING AND TREATING CANCER AND THERAPY-ASSOCIATED SIDE EFFECTSDecember 2020November 2024Abandon4711NoNo
17257070SOLID FORMS OF 2-(3,5-DICHLORO-4-((5-ISOPROPYL-6-OXO-1,6-DIHYDROPYRIDAZIN-3-YL)OXY)PHENYL)-3,5-DIOXO-2,3,4,5-TETRAHYDRO-1,2,4-TRIAZINE-6-CARBONITRILEDecember 2020November 2024Abandon4711NoNo
17134875HETERO-HALO INHIBITORS OF HISTONE DEACETYLASEDecember 2020August 2023Allow3110NoNo
17256318PYRIDOPYRIMIDINE COMPOUNDS AND METHODS OF THEIR USEDecember 2020January 2025Allow4921NoNo
17255451TRIAZOLOTRIAZINE DERIVATIVES AS A2A RECEPTOR ANTAGONISTSDecember 2020August 2023Allow3121NoNo
17255464TRIAZOLOTRIAZINE DERIVATIVES AS A2A RECEPTOR ANTAGONISTSDecember 2020August 2023Allow3221NoNo
17255054SALTS OF (S)-(5-CYCLOBUTOXY-2-METHYL-6-(1-(PIPERIDIN-4-YL)-1H-PYRAZOL-4-YL)-3,4-DIHYDROQUINOLIN-1(2H)-YL)(CYCLOPROPYL)METHANONE AND SOLID FORMS THEREOFDecember 2020October 2023Abandon3310NoNo
17254991SELECTIVE ESTROGEN RECEPTOR DEGRADERSDecember 2020June 2024Allow4230YesNo
17253373TOPICAL FORMULATIONS OF DGAT1 INHIBITORS AND THEIR METHODS OF USEDecember 2020May 2024Abandon4101NoNo
17253522OGA INHIBITOR COMPOUNDSDecember 2020May 2024Abandon4101NoNo
16972750NOVEL MOLECULE WITH ANTI-CANCER ACTIVITYDecember 2020May 2024Abandon4110NoNo
15734611Antifungal Cuticle Oil CompositionDecember 2020October 2024Abandon4620NoNo
17099514MODULATORS OF P97 AAA ATPASE ACTIVITYNovember 2020October 2024Abandon4721NoNo
16608723HETEROCYCLIC COMPOUNDS HAVING A CALCIUM-SENSING RECEPTOR ANTAGONISTIC ACTIVITYOctober 2020September 2024Allow5911YesNo
17073934COMPOSITIONS AND METHODS FOR TREATING GLIOBLASTOMA BY MODULATING A MGMT ENHANCEROctober 2020September 2024Abandon4711NoNo
17044866CELL-PENETRATING PEPTIDE-MULTIARM POL YETHYLENE GLYCOL-DRUG CONJUGATE HAVING TARGETING PROPERTY AND APPLICATION THEREOFOctober 2020May 2025Abandon5521NoNo
16979757SOLID OILY EXTERNAL COMPOSITIONSeptember 2020November 2024Abandon5040NoNo
169773052,6-DIMETHOXY-4-(5-PHENYL-4-THIOPHENE-2-YL-1H-IMIDAZOL-2-YL)-PHENOL (DPTIP) A SMALL MOLECULE INHIBITOR OF NEUTRAL SPHINGOMYELINASE 2 (nSMase-2) FOR THE TREATMENT OF NEURODEGENERATIVE AND ONCOLOGIC DISEASESSeptember 2020May 2023Allow3210NoNo
16976504OPHTHALMIC COMPOSITION COMPRISING DIQUAFOSOL AND CATIONIC POLYMERAugust 2020March 2025Abandon5450NoNo
16975292PHARMACEUTICAL COMPOSITIONS COMPRISING (2S)-N-{(1S)-1-CYANO-2-[4-(3-METHYL-2-OXO-2,3-DIHYDRO-1,3-BENZOXAZOL-5-yl)PHENYL]ETHYL}-1,4-OXAZEPANE-2-CARBOXAMIDEAugust 2020April 2024Allow4340YesNo
16970305PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) DEGRADATION / DISRUPTION COMPOUNDS AND METHODS OF USEAugust 2020March 2024Abandon4311NoNo
16955097SUBSTITUTED INDOLE COMPOUNDS USEFUL AS TLR INHIBITORSJune 2020August 2023Allow3841NoNo

Appeals Overview

No appeal data available for this record. This may indicate that no appeals have been filed or decided for applications in this dataset.

Examiner MOU, LIYUAN - Prosecution Strategy Guide

Executive Summary

Examiner MOU, LIYUAN works in Art Unit 1628 and has examined 96 patent applications in our dataset. With an allowance rate of 38.5%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 38 months.

Allowance Patterns

Examiner MOU, LIYUAN's allowance rate of 38.5% places them in the 4% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by MOU, LIYUAN receive 1.34 office actions before reaching final disposition. This places the examiner in the 27% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by MOU, LIYUAN is 38 months. This places the examiner in the 11% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +70.0% benefit to allowance rate for applications examined by MOU, LIYUAN. This interview benefit is in the 99% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 28.1% of applications are subsequently allowed. This success rate is in the 41% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 33.3% of cases where such amendments are filed. This entry rate is in the 41% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.

Petition Practice

When applicants file petitions regarding this examiner's actions, 23.1% are granted (fully or in part). This grant rate is in the 14% percentile among all examiners. Strategic Note: Petitions are rarely granted regarding this examiner's actions compared to other examiners. Ensure you have a strong procedural basis before filing a petition, as the Technology Center Director typically upholds this examiner's decisions.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.